Anavex Life Sciences Corp (AVXL)

[falconer66a]

A Big Alzheimer’s Trial is Ongoing

No AD drug will be approved based on tiny studies....

Are you suggesting, then, that the ongoing big double-blind Alzheimer’s clinical trial with blarcamesine is too “tiny” to validate the drug’s safety and efficacy?

After the unique MOA (mechanism of action) of the drug is proven in both pediatric and non-pediatric Rett patients, in the two Rett clinical trials, followed by similar positive results in the Alzheimer’s trial, what will then prevent regulatory approval (by the FDA or other)?

Things couldn’t be more favorably aligned. Each trial yields positive outcomes, mutually supporting the findings of previous trials. When the Alzheimer’s trial concludes, there will be no data upon which to deny blarcamesine’s approval. That should be some time in 2023. Given the eventual benefits to CNS patients and AVXL equity investors (not traders), we long-term holders of AVXL positions can patiently wait; with patience, for patients.